Affiliation: University of Texas Health Science Center
- Management of the neurological manifestations of APS--what do the trials tell us?Robin L Brey
Division of Medicine Neurology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive 7883, San Antonio, TX 78229 3900, USA
Thromb Res 114:489-99. 2004..To systematically review evidence from clinical trials about the management of neurological manifestations of Antiphospholipid Syndrome (APS)...
- Animal models for nervous system disease in systemic lupus erythematosusR L Brey
Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7883, USA
Ann N Y Acad Sci 823:97-106. 1997..Both approaches promise to identify predictors of specific nervous system manifestations that may suggest novel and more specific therapeutic interventions...
- Neuropsychiatric lupus: clinical and imaging aspectsRobin L Brey
Department of Medicine Neurology, University of Texas Health Science Center at San Antonio 78229 3900, USA
Bull NYU Hosp Jt Dis 65:194-9. 2007..Methods that evaluate metabolic processes and other functional imaging techniques have more promise as surrogates for central nervous system damage. This article reviews the current literature on clinical and imaging aspects of NPSLE...
- Antiphospholipid antibodies in young adults with strokeRobin L Brey
University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284 7883, USA
J Thromb Thrombolysis 20:105-12. 2005..Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss...
- New treatment option for the antiphospholipid antibody syndrome? More pleiotropic effects of the statin drugsR L Brey
Department of Medicine, Division of Neurology, University of Texas Health Science Center at San Antonio, TX 78229 3900, USA
J Thromb Haemost 2:1556-7. 2004
- Antiphospholipid antibodies and the brain: a consensus reportR L Brey
University of Texas Health Science Center at San Antonio, Department of Neurology, San Antonio, TX 78229, USA
Lupus 20:153-7. 2011..Recommendations are made regarding further research that is needed to clarify remaining uncertainties...
- Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002R L Brey
Department of Medicine, Division of Neurology, University of Texas Health Science Center San Antonio, Texas 78229 3900, USA
Lupus 12:508-13. 2003..In the absence of data to guide clinicians on the best treatment, we cannot make strong recommnendations as to optimal therapy, nor can we propose clear consensus treatment guidelines...
- Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndromeR L Brey
University of Texas Health Science Center at San Antonio, Texas 78284 7883, USA
J Autoimmun 15:133-8. 2000..In this mini-review, most of the neurologic syndromes with an actual or suspected association with aPL are considered. The role of aPL in the differential diagnosis of these syndromes is considered as well...
- Neuropsychiatric syndromes in lupus: prevalence using standardized definitionsR L Brey
Department of Medicine, Division of Neurology, San Antonio, TX 78229 3900, USA
Neurology 58:1214-20. 2002..The San Antonio Lupus Study of Neuropsychiatric Disease is a longitudinal study designed to characterize the spectrum of and important risk factors for specific neuropsychiatric systemic lupus erythematosus (NPSLE) syndromes...
- Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic strokeSteven R Levine
Department of Neurology, Mt Sinai School of Medicine, New York, NY 10029 6574, USA
JAMA 291:576-84. 2004..The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial...
- Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessonsEyal Muscal
Department of Medicine Neurology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
Curr Rheumatol Rep 10:67-73. 2008..Modifiable cardiac risk factors and valvular heart disease may worsen APS cerebrovascular outcomes. Adjunctive therapies (eg, statins, antimalarials, and angiotensin-converting enzyme inhibitors) warrant clinical trials...
- Antiphospholipid antibodies and stroke in young womenRobin L Brey
University of Texas Health Science Center, San Antonio, Tex 78229 3900, USA
Stroke 33:2396-400. 2002..Antiphospholipid antibodies have been associated with ischemic stroke in some but not all studies...
- Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS studyKumar Rajamani
Department of Neurology, Wayne State University, Detroit, MI 48201, USA
Stroke 40:2337-42. 2009..PFO is associated with cryptogenic ischemic stroke. Also, the presence of aPL is associated with ischemic cerebrovascular disease...
- Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damageHayden Zaccagni
Department of Medicine, Division of Neurology and GRECC, South Texas Veterans Health Care System, San Antonio, TX, USA
Front Biosci 9:1654-9. 2004..Elevated levels of all soluble adhesion molecule levels correlated with abnormal levels of antiphospholipid antibodies, which are associated with some NPSLE manifestations and have been shown to upregulate adhesion molecule expression...
- Neurologic manifestations of the antiphospholipid syndromeJose F Roldan
School of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
Curr Rheumatol Rep 9:109-15. 2007....
- Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE)David Hermosillo-Romo
Division of Neurology 7883, 7703 Floyd Curl Drive, San Antonio, Texas 78229 3900, USA
Best Pract Res Clin Rheumatol 16:229-44. 2002..The management of NPSLE includes symptomatic and/or immunosuppressive treatment strategies depending on the specific presenting neuropsychiatric symptoms and whether these occur in the setting of an SLE disease activity flare...
- Neuropsychiatric involvement in systemic lupus erythematosusDavid Hermosillo-Romo
University of Texas Health Science Center at San Antonio, Division of Neurology, Mail Stop 7883, 7703 Floyd Curl Drive, San Antonio, TX 79220 3900, USA
Curr Rheumatol Rep 4:337-44. 2002..Cognitive dysfunction and psychiatric disorders are the two most common manifestations. The work-up and treatment of nervous system syndromes are also discussed...
- Both migraine and motion sickness may be due to low brain levels of serotoninRobin L Brey
Neurology 65:E9-10. 2005..In this issue of Neurology, Drummond reports on a study that evaluated whether low brain levels of serotonin trigger motion sickness in people with and without migraine. More information about migraine can be found on the next page...
- Patient Page. Clinical research needs YOU to help develop new cures!Robin L Brey
Neurology 63:E1. 2004
- Severe neurologic complications after hematopoietic (peripheral blood) stem cell transplantation in childrenRobin L Brey
Neurology 59:E13-5. 2002
- Neuropsychiatric systemic lupus erythematosus: miles to go before we sleepRobin L Brey
Neurology 61:9-10. 2003
- Patient page. Memory problems after epilepsy surgeryStephen L Holliday
Neurology 60:E3-5. 2003
- PREDICTORS OF NEUROPSYCHIATRIC SLEROBIN BREY; Fiscal Year: 2004..The information gained will bridge important gaps in our knowledge about NS involvement in SLE and will lead to new hypothesis-driven studies of etiopathogenesis and treatment. ..
- MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEARROBIN BREY; Fiscal Year: 2006..Much will be learned about the relative importance of genetic factors and autoantibodies on vascular disease risk in SLE that is likely to apply to other populations also at increased risk for cerebral ischemia and vascular dementia. ..
- Cognitive Function in SLE (COGNITION)Robin L Brey; Fiscal Year: 2010..The information that will be gained from this study is essential for the successful discovery of biological processes that impact on cognitive function in SLE that could be potentially amenable to disease-reversing therapies. ..